Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Silbermann

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Blood|September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Badros, Laahn Foster, Larry D Anderson, et al.
British Journal of Haematology|September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN studyDouglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2021
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter AnalysisArtur Jurczyszyn, Jorge J Castillo, Magdalena Olszewska-Szopa, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Future Oncology (London, England)|October 25, 2024
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myelomaPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Blood|September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Badros, Laahn Foster, Larry D Anderson, et al.
British Journal of Haematology|September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN studyDouglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2021
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter AnalysisArtur Jurczyszyn, Jorge J Castillo, Magdalena Olszewska-Szopa, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Future Oncology (London, England)|October 25, 2024
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myelomaPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.
Pageof 5